THE WELINK.CARE LABEL HAS BEEN AWARDED TO

Andaman7

ON THE 2ND OF NOVEMBER 2020

WITH THE HIGH DISRUPTION SCORE OF 74 %

WeLink.Care Label

_____
Dr. Thierry Vermeeren, CEO

The WeLink.Care label uses a composite index scoring the disruption value of a digital solution use case in the daily health practice.
Our expert team has reviewed the preselected digital solution with a set of 35 points of measure, based on interviews, documents research and analysis.

ANDAMAN7 RECEIVES THE WELINK.CARE LABEL

Introduction

Andaman7 has been awarded the prestigious WeLink.Care Label, a mark of distinction in the field of digital health innovation. This recognition affirms Andaman7's commitment to transforming healthcare practices by enhancing patient empowerment and improving communication between stakeholders across the care continuum. By achieving the WeLink.Care Label, Andaman7 joins an elite group of solutions validated for their disruptive potential and their contribution to improving healthcare delivery.

About the WeLink.Care Label

The WeLink.Care Label was introduced in 2020, during the COVID-19 pandemic, as part of an initiative to support the global healthcare sector in addressing unprecedented challenges. Initially focused on identifying and cataloging e-health solutions to combat the pandemic, the label quickly gained recognition as a benchmark for innovation and effectiveness in healthcare technology. Solutions granted the label are those that demonstrate exceptional potential to disrupt and enhance healthcare practices.

Today, the WeLink.Care Label represents a rigorous evaluation standard based on scientific methodology. Solutions are assessed across multiple dimensions, including their economic viability, maturity, capacity to influence healthcare practices, and user experience for both patients and professionals. This label not only highlights groundbreaking innovations but also ensures that certified solutions meet the high standards necessary to positively impact global healthcare.

The Evaluation Process

The evaluation process for the WeLink.Care Label is a multi-stage methodology designed to assess the full spectrum of a solution's impact. It begins with a comprehensive review of internal documentation and a series of interviews with the solution's development team. These steps provide insights into the solution's design, innovation, and market readiness.

Subsequent stages involve external validation, including interviews with users, healthcare professionals, and other stakeholders. This ensures the analysis captures real-world usage and feedback. The methodology also incorporates data points from scientific studies and industry benchmarks to establish the solution's credibility and effectiveness.

Every evaluation is conducted by a certified expert trained in the WeLink.Care methodology. This process ensures consistency and objectivity while leveraging the expert's deep knowledge of digital health solutions. Evaluators look at factors such as user experience, operational feasibility, and the solution's ability to integrate with existing healthcare ecosystems.

The final assessment synthesizes data from all sources into a disruption score, highlighting the solution's strengths and identifying areas for improvement. This score provides a clear, actionable framework for stakeholders to understand the solution's potential and guide its further development. Solutions achieving the WeLink.Care Label are recognized as industry leaders, well-positioned to address current and future challenges in healthcare.

ANDAMAN7

Introduction to the company

Founded in 2014 in Belgium, Andaman7 emerged as a pioneering force in the e-health industry, driven by a personal mission of its co-founder and CEO, Vincent Keunen. He envisioned a patient-centered solution to streamline healthcare data management while maintaining privacy and security. The company, operating under the trade name A7 Software, focuses on bridging gaps in healthcare communication and data accessibility, fostering collaboration among patients, healthcare professionals, and researchers. Andaman7 has expanded its operations internationally, offering innovative tools that empower individuals to take control of their healthcare journey. The company's flagship product—a mobile electronic health record—incorporates cutting-edge technology and a commitment to data privacy, ensuring its solutions cater to diverse healthcare stakeholders. Through partnerships with medical institutions, clinical research organizations, and pharmaceutical companies, Andaman7 continues to redefine how healthcare data is exchanged and utilized.

The Solution

Andaman7 offers a unique platform that serves as a dual-function mobile application—a Personal Health Record (PHR) for patients and an Electronic Health Record (EHR) for healthcare professionals. It empowers patients to centralize, manage, and share their medical information securely while enabling professionals to access and contribute to a unified health record. By combining official medical records with patient-reported outcomes and real-world data, the platform creates a comprehensive and continuously updated health profile. The solution employs a peer-to-peer architecture for data exchange, ensuring no data is stored in the cloud. This innovative approach enhances security and privacy, placing full control of sensitive information in the hands of patients. Andaman7's interoperability capabilities make it a versatile tool, seamlessly integrating with existing healthcare systems and research databases.

Features and Benefits

Andaman7 is rich in features designed to address the needs of both patients and healthcare professionals. Patients can consolidate medical history, track health metrics, set reminders for medication or vaccinations, and even share specific data with trusted parties, such as family members or doctors. For healthcare providers, the app offers access to accurate, real-time patient data, enhancing diagnostic accuracy and treatment outcomes. A standout feature of Andaman7 is its capability to support clinical research. By enabling patients to share anonymized data with research organizations, the platform accelerates the development of innovative treatments while maintaining ethical standards. This functionality benefits both pharmaceutical companies seeking data for trials and patients contributing to the advancement of medicine. The solution's user-friendly interface, combined with its robust security measures, ensures an intuitive and trustworthy experience for all users.

Compliance and Future Outlook

Andaman7 adheres to strict compliance standards, including GDPR in Europe and HIPAA in the United States, demonstrating its commitment to maintaining the highest levels of data security and privacy. Its decentralized architecture aligns with these standards by minimizing data exposure risks. Looking ahead, Andaman7 is poised to expand its integration capabilities, furthering its role as a key player in advancing interoperability in digital health. By continuously incorporating user feedback and aligning with evolving global health needs, Andaman7 remains at the forefront of e-health innovation, ready to tackle emerging challenges in patient care and clinical research.

DISRUPTION SCORE

The disruption score for Andaman7 reflects its strong potential in digital health innovation. The solution is fully commercialized, enabling patients to access and manage their health records securely on their smartphones. While its decentralized approach empowers users, the need for manual data integration from hospitals remains a limitation. Financially, Andaman7 has shown consistent growth over the past three years. The absence of scientific studies highlights an opportunity for further validation of its impact.

BUSINESS PERFORMANCE
**92%**
|~ very good ~|

CHANGE OF PRACTICES
64%
|~ significant ~|

## DISRUPTION POTENTIAL
74%
|~ high ~|

SOLUTION MATURITY
58%
|~ medium ~|

USER EXPERIENCE
83%
|~ very good ~|

BUSINESS MODEL

Andaman7's business model reflects a strategic evolution, leveraging its robust financial growth over the past three years. The company has diversified its focus, targeting pharmaceutical companies by offering tools to streamline clinical trial data management. This complements its core proposition as a "medical record in the patient's pocket," combining personal health empowerment with value-added services for research. This dual-market approach positions Andaman7 for sustained growth and broader adoption in healthcare innovation.

BUSINESS MODEL

|~ very good ~|

BUSINESS PERFORMANCE

92%

|~ very good ~|

COMMERCIAL READINESS LEVEL

9

|~ model validated ~|

SOLUTION MATURITY

Andaman7 is a fully developed and commercialized solution, initially designed as a "medical record in the patient's pocket." Over time, it has expanded to support clinical trial efficiency by enabling the collection of patient-reported outcomes (PROMS) and providing clinical trial managers with valuable real-world evidence. However, the lack of published scientific studies on its effectiveness limits its maturity score, presenting an opportunity for further validation to enhance its credibility and impact.

CLINICAL TRIALS

|~ no published studies ~|

**PREMS & PROMS**

|~ insufficient ~|

DESIGN APPROACH

|~ adequate ~|

SOLUTION MATURITY

58%

|~ medium ~|

TECHNOLOGY READINESS LEVEL

9

|~ product deployed ~|

CHANGE OF PRACTICES

Andaman7 significantly enhances patient access to their medical data, promoting continuity of care by centralizing records on a user-controlled platform. However, data quality and structuring rely on hospital processes, requiring patients to manually request updates from each institution. Built on international standards like FHIR, Andaman7 is well-positioned for growth in markets like the USA, although adoption may face challenges in European regions with proprietary communication protocols. This adaptability highlights its potential for transformative healthcare practices.

PRACTICES MEASURE POINTS

|~ 11 relevant measure points ~|

CHANGE OF PRACTICES

64%

|~ significant ~|

USER EXPERIENCE : THE PROFESSIONAL AND PATIENT PERSPECTIVE

Andaman7 offers a user-friendly and secure platform, empowering patients to manage their health data on their smartphones without requiring training. The solution integrates with connected devices and supports participation in clinical studies, fostering patient engagement. While healthcare professionals can access patient-shared data for a broader perspective, the app functions primarily as a patient tool, as it lacks integration with Belgium's Digital Health Networks. This focus limits its utility as a fully collaborative professional resource.

PROFESSIONAL EXPERIENCE

60%

|~ good ~|

PATIENT EXPERIENCE

USER EXPERIENCE

83%

|~ very good ~|

100%

|~ very good ~|

LINKS AND RESOURCES

https://www.andaman7.com/fr

https://label.welink.care/

_____

This report is based on the information provided by the scored company, input from various stakeholders, and the application of the WeLink.Care© methodology by OZConsulting. The findings, scores, and evaluations presented are intended solely for informational purposes and do not constitute a guarantee or endorsement of the quality, effectiveness, or commercial viability of the evaluated digital health solution.

The conclusions are drawn from the data available at the time of the study and may not reflect subsequent changes. OZConsulting assumes no responsibility for the accuracy or completeness of the information provided by the scored company or any third parties involved. Any reliance on this report is at the reader's own risk.

The content of this report is protected under copyright law. No part of this report may be reproduced, distributed, or used for commercial purposes without prior written permission from OZC. The WeLink.Care© methodology and scoring system are proprietary to OZConsulting.

_____